Active Cancer NIHR-supported project Digestion, Kidneys & Other Organs

A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)

Funder NIHR (part of DHSC)
Recipient organisation NIHR Barts Biomedical Research Centre
NIHR support Recorded as supported by this research centre
Period Jan 2025 — Sept 2026

About this grant

This summary is based on the grant title only — the full abstract was not available.

No substantive source abstract was published for this research project funded by NIHR.

Researchers

Rowan Miller (Principal Investigator)

Related Research

Grants with similar aims, by meaning.

A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigators Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy
Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapy
An Open-Label, Phase 1b Study of SL-172154 (SIRP?-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression.

Original classification

Precision Cancer Care

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.